



## **N30 Pharma Announces Presentation at Gordon Research Conference**

Boulder, Colorado, August 9, 2010-- N30 Pharmaceuticals, LLC announced a presentation this week at the 2010 Medicinal Chemistry Gordon Research Conference at Colby-Sawyer College in New Hampshire. The presentation by Xicheng Sun, PhD is entitled "Discovery of S-Nitrosoglutathione Reductase (GSNOR) Inhibitors as Potential Agents to Treat Asthma and Related Diseases." It describes the structure-activity relationship and pharmacologic properties of N30 Pharma's novel, reversible GSNOR inhibitors.

This new class of small molecule inhibitors preserve levels of S-nitrosoglutathione (GSNO), an endogenous substrate of GSNOR. GSNO is a key signaling molecule in the body found to be of importance in respiratory disease, gastrointestinal disease, control of breathing, and cardiovascular function. N30 Pharma's highly potent, selective and reversible GSNOR inhibitors slow GSNO catabolism. N30 Pharma's proprietary compounds provide a platform of drug candidates that can be administered orally, intravenously, and by inhalation for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).

N30 Pharma has announced approval by the FDA to enter Phase 1 human testing of its first GSNOR inhibitor, N6022.

### **About N30 Pharma**

N30 Pharma is a privately held biopharmaceutical company headquartered in Boulder, Colorado. N30 Pharma focuses on the discovery and development of proprietary drugs that provide therapeutic advantage over current treatment for major human diseases such as asthma, COPD and IBD. The Company's strategy is to excel at discovery research and early-stage clinical development, and then establish one or more partnerships with leading pharmaceutical companies to further the advancement of its lead clinical development candidates.

### **Contact Information**

[info@n30pharma.com](mailto:info@n30pharma.com)

Gary J. Rosenthal, PhD  
EVP Discovery Research, N30 Pharma  
(720) 945 7712

Charles Scoggin, M.D.  
CEO, N30 Pharma  
(720) 945 7721